Biocept, Inc on watch for Big moveLarge independent physician association serving California now offers access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer
SAN DIEGO, Feb. 10, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered into an agreement with a California-based independent physician association (IPA) to provide its liquid biopsy testing services to physicians and patients in their network. Biocept's Target Selector™ offering includes the choice of individual biomarker tests or a larger liquid biopsy panel, enabling physicians to select the best approach for each patient.
\We are very pleased to become a provider for this well-respected IPA, which offers comprehensive and cutting-edge medical care to its member physicians and their patients," said Michael Nall, Biocept's President and CEO. "Now, more people in California will have access to our Target Selector™ liquid biopsy testing services, which can help physicians identify actionable biomarkers in patients diagnosed with cancer and design personalized treatment programs in order to improve outcomes. We expect to announce agreements with other value-based healthcare delivery systems as the year progresses."
About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information,
Trade ideas
$BIOC wave 1 Wave 1 seems to be complete and preparing for the next wave with a projected T.P. $ 0.66 and nextT.P. levels of %0.93, $1.5, $3.00 for the near term T.P.
BIOC Still Failing To FillCOMMENTARY
BIOC is one of those penny stocks that have individual, good days. But when it comes to putting together a string of bullish action, it has yet to reach that milestone. Furthermore, though volume is good, the company still needs to execute further in my opinion. Either way. It's a good day today but would like to put this on a 30 day time clock and see where things are, at that time.
QUOTE
"On Tuesday (1-14) the company reported that its Target Selector™ assays are now available to doctors. The goal is for these doctors to use the Target Selector™ to evaluate cerebrospinal fluid of patients and check for the presence of circulating tumor cells for patients with breast or lung cancer suspected of brain or nervous system metastases.According to the company, the presence of tumor cells in the central nervous system might indicate brain metastases that can happen when cancer has spread to these locations. Thanks to this update, shares of Biocept rallied."
QUOTE Source: Top Penny Stocks To Watch Right Now; 1 Up Over 100% Since November
Clinical Validation and Commercial LaunchBiocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer
finance.yahoo.com
Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis.
$BIOC Keep on watchlist, could be very volatile $$$%%%Shares of Biocept Inc. BIOC, 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid biopsy panel developed for lung cancer. Trading volume spiked to 60.9 million shares, compared with the full-day average of about 733,000 shares. the company said in a statement. The stock was still down 73% over the past 12 months, so don't be concerned if you missed the initial rally, as it gave most of it back in the days that followed.
We will have a strong watch on this as the stock has held good support so we hope for renewed positive price action.
COMPANY PROFILE
Biocept , Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample
$BIOC KEEP A CLOSE WATCH THIS COULD MOVE VERY FAST.*****WE KEEP ALERTS SET ON THIS NAME AND BUY ORDER IN PLACE, RUMOR HAS IT THERE IS A MOVE COMING SOON, WITH MASSIVE UPSIDE POTENTIAL******
James mc Carthy from MAxim recently maintained his buy rating and initiated a $3 price target citing.
“Biocept reported 1Q19 with ~$1M in revenue and a net loss of $5.9M. The company ended the period with $14.8M in cash on the balance sheet.”
BIOCEPT INC.
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample
i'm wrong or it's an flag pattern ?? BIOCPlease help me, did i find an flag pattern on that stock, i'm new in that kind of analyse and i learn again.
What I like about #BIOC as an overnight swing.What I like about BIOC:
1. Higher lows on the daily
2. RSI crossed above the 50
3. MACD still bullish
4. Range to 50ma within reach.
5. Break above 50ma could fill gap to .49
6. MA's in alignment.
7. Showed up on EOD scan - 87% chance of running tomorrow.
BIOC , Long ? The stock is a big % Gainer , it will be in the watchlist of many traders this week and might be going up after its apocalypse
The price now is in a rang between 1.80 and 1.40
If it will break The 1.80 , we have a great probability to go long to the 3.37 ( Last Big top ) forming perhaps a double top for another colapse ( Or not )
If it will break the 1.40 , we will go short to the 1.00
DONT FORGET , We are traders , not analysts , we must have in the same time The long gun and the short gun ready for any cenario and the market will decide which gun we will pull .
Biocept - Buy the negativity. The revenue doesn't mind. Biocept has the best-in-breed liquid biopsy testing in the Immuno-Oncology space. Market cap is 70 million, but it's going to be several billion in a few years if they don't get bought out first.
Revenue in the second quarter ended 6/30/2016 increased 8 fold to 663,000 from 77,000 last year. This revenue only included half of June for their commerical launch of its PD-L1 protein expression test in mid-June. Frankly, I’m surprised that they didn’t burn through a lot more cash and issue a lot more shares considering their disastrous dilution last year. Their expenses didn’t go up as much as I was expecting either, and they’re sitting on $3.8 million in cash.
BIOC Measured Move ResumingThe pennant consolidation is about over, it is ready to break out and make the next leg of its upward journey starting out with a measured move. Since it is so close to the apex of the pennant with a doji, anyone short should consider covering immediately.
